Schrödinger, Inc. (SDGR) Guidance & Earnings Results
On 2026-08-05 Schrödinger, Inc. raised guidance: "Drug discovery revenue guidance raised from $55-65M to $65-75M; ACV guidance maintained at…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SDGRSchrödinger, Inc.Follow SDGR — free
—
Price chart with a free account
- Market cap
- 593.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 5 Aug 26 | Raised | Drug discovery revenue guidance raised from $55-65M to $65-75M; ACV guidance maintained at $218-228M · full year |
| 5 May 26 | Reaffirmed | FY2026 ACV $218M-$228M; Drug discovery revenue $55M-$65M; Q2 ACV $19M-$23M · full year |
| 25 Feb 26 | Raised | 2026 software ACV guidance $218-228M (10-15% growth) |
| 5 Nov 25 | Mixed | Software growth 8-13% (lowered); drug discovery revenue $49-52M (raised). · full year |
| 6 Aug 25 | Mixed | FY2025 software revenue growth 10-15%; drug discovery revenue $45-50M; software gross margin 74-75%; operating expenses lower than 2024; cash used for operating activities significantly lower than 2024; Q3 2025 software revenue $36-40M · full year |
Schrödinger, Inc. — questions
- What guidance did Schrödinger, Inc. give?
- On 2026-08-05: "Drug discovery revenue guidance raised from $55-65M to $65-75M; ACV guidance maintained at $218-228M"
- When does Schrödinger, Inc. report earnings?
- Schrödinger, Inc.'s next earnings report is expected on 2026-11-04.
Every figure on this page comes from Schrödinger, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.